Druggable Targets in Diseases Due to Mucociliary Dysfunction and Bronchiectasis

Chiesi Farmaceutici S.p.A, one of the top 50 pharmaceutical companies in the world, is seeking novel targets/therapeutics for respiratory diseases with a clinical unmet need, such as chronic obstructive pulmonary disorder (COPD), non–CF bronchiectasis and mucociliary dysfunction, that have a competitive edge on current treatments.

Approaches of Interest:

- Novel druggable targets and therapeutic approaches for respiratory diseases including COPD, non–CF bronchiectasis, mucociliary dysfunction, primary ciliary dyskinesia etc.
- Open to different modalities, including small molecules, RNA-based or peptide-based therapeutics and antibodies

Out of Scope:

- Targets and therapeutic approaches for asthma and CF-related bronchiectasis
- Gene therapy and cell therapy approaches
- Opportunities related to medical devices, diagnostics and monitoring

Development Stages of Interest:

- Opportunities from basic research to the preclinical research phase are within scope, provided that there is experimental validation of the target/therapeutic
- Opportunities with in vivo validation are of the highest interest, although opportunities with in vitro or ex vivo validation (e.g., airway liquid interface cultures, precision-cut lung slices etc.) will still be considered

Submission Information:

Submission of one-page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g., relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration:

Chiesi Farmaceutici S.p.A is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. They are flexible in how they engage with academic institutions. Example outcomes include licensing assets, co-development, and research collaborations.